As of 2024-12-12, the Intrinsic Value of Zentalis Pharmaceuticals Inc (ZNTL) is
-12.58 USD. This ZNTL valuation is based on the model Peter Lynch Fair Value.
With the current market price of 3.50 USD, the upside of Zentalis Pharmaceuticals Inc is
-459.37%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
-12.58 USD
Intrinsic Value
ZNTL Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| Fair Value |
-12.58 - -12.58 |
-12.58 |
-459.37% |
| P/E |
(70.79) - (78.64) |
(69.43) |
-2083.7% |
| DDM - Stable |
(15.31) - (38.61) |
(26.96) |
-870.4% |
| DDM - Multi |
(0.41) - (0.77) |
(0.53) |
-115.1% |
ZNTL Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
249.44 |
| Beta |
1.67 |
| Outstanding shares (mil) |
71.27 |
| Enterprise Value (mil) |
208.12 |
| Market risk premium |
4.60% |
| Cost of Equity |
12.68% |
| Cost of Debt |
5.00% |
| WACC |
8.84% |